Please assess the completion status of the following clinical trial:

Trial Title: Microbiota Restoration Therapy for Recurrent Clostridium Difficile-associated Diarrhea

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* ≥ 18 years~* Medical record documentation of CDAD either: a) at least two recurrences after a primary episode and have completed at least two rounds of standard-of-care oral antibiotic therapy or b) have had at least two episodes of severe CDAD resulting in hospitalization.~* Willing and able to have an enema(s).~* Already taking or will start a course of oral antibiotics for CDAD symptoms for 10-14 days, including at least seven days of oral vancomycin.~* Willing and able to complete the required subject diary.~Exclusion Criteria:~* Continued (uncontrolled) CDAD after completing a 10-14 day course of oral antibiotics.~* Requires antibiotic therapy for a condition other than CDAD.~* Previous fecal transplant prior to study enrollment.~* History of inflammatory bowel disease (IBD), e.g., ulcerative colitis, Crohn's disease, or microscopic colitis.~* History of irritable bowel syndrome (IBS).~* History of chronic diarrhea.~* History of celiac disease.~* History of cirrhosis of the liver or ascites.~* Disease symptoms caused by a confirmed intestinal pathogen other than Clostridium difficile.~* Has a colostomy.~* Intraabdominal surgery within the last 60 days.~* Evidence of active, severe colitis.~* History of short gut syndrome or motility disorders.~* Requires the regular use of medications that affect bowel motility (e.g., metoclopramide, narcotics, loperamide).~* Planned therapy in the next 3 months that may cause diarrhea (e.g., chemotherapy).~* Planned surgery requiring perioperative antibiotics within 6 months of study enrollment.~* Life expectancy of \< 12 months.~* Compromised immune system, e.g., HIV infection (any CD4 count); AIDS-defining diagnosis or CD4 \<200/mm3; inherited/primary immune disorders; immunodeficient or immunosuppressed due to a medical condition or medication; current or recent (\< 90 days) treatment with chemotherapy; or current or recent (\< 90 days) treatment with immunosuppressant medications.~* Taking steroids (≥ 20 mg a day) or is expected to be on steroids for more than 30 days after enrollment.~* Neutropenia (white blood cell count \<1000 cells/µL).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- RBX2660 (microbiota suspension) (Type: EXPERIMENTAL): enema-based delivery of RBX2660

Based on this trial design, predict the completion outcome and termination type (if applicable).